ODI Pharma AB (ODI.ST)
SEK 2.76
(-8.0%)
SEK 2.76
(-8.0%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.63 Million | -5.1 Million | -7.37 Million | -6.06 Million | -4.74 Million | -3.35 Million |
| Net Income | 355.97 Thousand | -6.9 Million | -7.23 Million | -3.98 Million | -4.96 Million | -3.63 Million |
| Depreciation & Amortization | 2926.00 | 4114.00 | 5588.00 | 6975.00 | 12.26 Thousand | 2104.00 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -3.78 Million | 881.83 Thousand | -190.76 Thousand | -1.61 Million | 63.6 Thousand | 37.49 Thousand |
| Other non-cash items | 3.57 Million | 37.69 Thousand | 251.8 Thousand | 1.16 Million | 100.48 Thousand | 204.16 Thousand |
| Investing Cash Flow | - | - | -4109.00 | - | -24.35 Thousand | -9712.00 |
| Investments in PPE | 3.63 Million | - | -4109.00 | - | -24.35 Thousand | -9712.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 454.47 Thousand | 4.06 Million | - | 258.5 Thousand | 20.85 Million | - |
| Debt repayment | -454.47 Thousand | -4.06 Million | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 258.5 Thousand | 20.85 Million | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | -10.55 Million | 330.89 Thousand | -154.95 Thousand | -665.6 Thousand | -286.78 Thousand | -39.91 Thousand |
| Accounts payables | 5.96 Million | 308.5 Thousand | 653.89 Thousand | 97.87 Thousand | 350.39 Thousand | 77.4 Thousand |
| Inventory | 807.93 Thousand | 242.43 Thousand | -689.7 Thousand | -1.04 Million | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 6.49 Million | 7.36 Million | 14.62 Million | 20.51 Million | 4.42 Million | 7.78 Million |
| Cash at end of period | 2.63 Million | 6.49 Million | 7.36 Million | 14.62 Million | 20.51 Million | 4.42 Million |
| Capital Expenditure | 3.63 Million | - | -4109.00 | - | -24.35 Thousand | -9712.00 |
| Effect of forex changes on cash | - | 164.38 Thousand | 121.34 Thousand | -85.03 Thousand | 8757.00 | - |
| Net cash flow / Change in cash | -3.85 Million | -874.98 Thousand | -7.25 Million | -5.88 Million | 16.09 Million | -3.36 Million |
| Free Cash Flow | - | -5.1 Million | -7.37 Million | -6.06 Million | -4.77 Million | -3.36 Million |
| Breakdown | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 355.97 Thousand | -1.2 Million | 1.29 Million | 946.53 Thousand | -1.44 Million | -6.9 Million |
| Depreciation & Amortization | 2926.00 | 721.00 | 725.00 | 747.00 | 747.00 | 4114.00 |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -3.78 Million | -2.91 Million | -1.4 Million | 442.52 Thousand | 101.07 Thousand | 881.83 Thousand |
| Other non-cash items | 3.57 Million | 3.43 Million | 1.59 Million | -595.26 Thousand | -94.52 Thousand | 37.69 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | 3.61 Million | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 454.47 Thousand | 454.47 Thousand | - | - | - | 4.06 Million |
| Debt repayment | -454.47 Thousand | -454.47 Thousand | - | - | - | -4.06 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | -10.55 Million | -354.21 Thousand | -10.31 Million | -85.9 Thousand | 200.8 Thousand | 330.89 Thousand |
| Accounts payables | 5.96 Million | -2.91 Million | 8.9 Million | 70.24 Thousand | -100.79 Thousand | 308.5 Thousand |
| Inventory | 807.93 Thousand | 348.69 Thousand | - | 458.18 Thousand | 1060.00 | 242.43 Thousand |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 6.49 Million | 5.92 Million | 6.52 Million | 5.12 Million | 6.49 Million | 7.36 Million |
| Cash at end of period | 2.63 Million | 2.63 Million | 5.92 Million | 6.52 Million | 5.12 Million | 6.49 Million |
| Capital Expenditure | - | 3.61 Million | - | - | - | - |
| Effect of forex changes on cash | - | - | 37.43 Thousand | 16.56 Thousand | -25.02 Thousand | 164.38 Thousand |
| Net cash flow / Change in cash | -3.85 Million | -3.29 Million | -591.96 Thousand | 1.39 Million | -1.36 Million | -874.98 Thousand |
| Free Cash Flow | -3.63 Million | - | 73.01 Thousand | 1.23 Million | -1.33 Million | -5.1 Million |
WLYW
PSGTY
GE
CGI
PSA-PK
FAGR